OVAS vs. PRLD, NBTX, EPIX, TSVT, GBIO, TRVI, PYXS, XBIT, ME, and STTK
Should you be buying OvaScience stock or one of its competitors? The main competitors of OvaScience include Prelude Therapeutics (PRLD), Nanobiotix (NBTX), ESSA Pharma (EPIX), 2seventy bio (TSVT), Generation Bio (GBIO), Trevi Therapeutics (TRVI), Pyxis Oncology (PYXS), XBiotech (XBIT), 23andMe (ME), and Shattuck Labs (STTK). These companies are all part of the "medical" sector.
Prelude Therapeutics (NASDAQ:PRLD) and OvaScience (NASDAQ:OVAS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation, risk and community ranking.
Prelude Therapeutics has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, OvaScience has a beta of 3.11, meaning that its share price is 211% more volatile than the S&P 500.
OvaScience received 249 more outperform votes than Prelude Therapeutics when rated by MarketBeat users. Likewise, 63.87% of users gave OvaScience an outperform vote while only 47.17% of users gave Prelude Therapeutics an outperform vote.
OvaScience has higher revenue and earnings than Prelude Therapeutics.
Prelude Therapeutics presently has a consensus price target of $4.75, suggesting a potential downside of 17.96%. Given OvaScience's higher probable upside, analysts clearly believe Prelude Therapeutics is more favorable than OvaScience.
In the previous week, Prelude Therapeutics had 2 more articles in the media than OvaScience. MarketBeat recorded 2 mentions for Prelude Therapeutics and 0 mentions for OvaScience. OvaScience's average media sentiment score of 1.89 beat Prelude Therapeutics' score of 0.00 indicating that Prelude Therapeutics is being referred to more favorably in the media.
Prelude Therapeutics has a net margin of 0.00% compared to Prelude Therapeutics' net margin of -10,128.37%. Prelude Therapeutics' return on equity of -47.06% beat OvaScience's return on equity.
79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 22.5% of OvaScience shares are owned by institutional investors. 62.8% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 7.4% of OvaScience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
OvaScience beats Prelude Therapeutics on 7 of the 13 factors compared between the two stocks.
Get OvaScience News Delivered to You Automatically
Sign up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OVAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OvaScience Competitors List
Related Companies and Tools
Free OVAS Stock Alerts